Article
Pharmacology & Pharmacy
Valeriya Gushchina, Nadja Kupper, Michael Schwarzkopf, Gitta Frisch, Karina Piatek, Cornelia Aigner, Alexandra Michel, Hemma Schueffl, Luca Iamartino, Taha Elajnaf, Teresa Manhardt, Andrea Vlasaty, Petra Heffeter, Marcella Bassetto, Enikoe Kallay, Martin Schepelmann
Summary: The activation of CaSR induces the activation of the PGE(2) pathway, but with different effects in vitro and in vivo. This may be due to the different microenvironment in vivo compared to in vitro, specifically the presence of a CaSR-responsive immune system. Calcilytics, which inhibit ligand-mediated CaSR signaling, could be considered for novel therapies against inflammatory bowel disease.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pediatrics
Julie Bernardor, Sacha Flammier, Jean-Pierre Salles, Cyril Amouroux, Mireille Castanet, Anne Lienhardt, Laetitia Martinerie, Ivan Damgov, Agnes Linglart, Justine Bacchetta
Summary: In this study, the French experience in using Cinacalcet for pediatric primary hyperparathyroidism (PHPT) was reported. The results showed that Cinacalcet can effectively control hypercalcemia and parathyroid hormone (PTH) levels without significant side effects.
FRONTIERS IN PEDIATRICS
(2022)
Article
Biochemistry & Molecular Biology
Martin Schepelmann, Nadja Kupper, Marta Sladczyk, Bethan Mansfield, Teresa Manhardt, Karina Piatek, Luca Iamartino, Daniela Riccardi, Benson M. Kariuki, Marcella Bassetto, Eniko Kallay
Summary: The study demonstrated that pro-inflammatory effects in colon cancer cells are mediated through CaSR activation, and non-CaSR selective enantiomer will be a valuable tool for investigations in CaSR-mediated processes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
Olga Radulova-Mauersberger, Julia Kessler, Ulrich Kessler, Katrin Stange, Sandra Korn, Jurgen Weitz, Ulrich Bork
Summary: The aim of this study was to investigate the impact of preoperative cinacalcet therapy on intraoperative parathyroid hormone (IOPTH) monitoring during surgery for primary hyperparathyroidism (pHPT). The retrospective analysis of 72 patients showed that the use of cinacalcet did not affect the value of IOPTH monitoring.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Urology & Nephrology
Aileen X. Wang, Sai Liu, Maria E. Montez-Rath, Glenn M. Chertow, Colin R. Lenihan
Summary: This study aims to examine the incidence, associations, and outcomes of posttransplant parathyroidectomy and calcimimetic use in a cohort of Medicare-insured US kidney transplant recipients. The study found that the rate of posttransplant parathyroidectomy remained stable over time, while the use of calcimimetic increased during the study period. Long dialysis vintage and pre-transplant calcimimetic use were strongly associated with posttransplant parathyroidectomy and calcimimetic use. Roughly 1 in 4 patients were hospitalized within 90 days of posttransplant parathyroidectomy, with hypocalcemia-related diagnoses being the most common complication. Parathyroidectomy was not associated with an increase in acute kidney injury compared to calcimimetic initiation.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2023)
Review
Medicine, General & Internal
Jakob Hoeppner, Kathrin Sinningen, Adalbert Raimann, Barbara Obermayer-Pietsch, Corinna Grasemann
Summary: This review focuses on the genetic and pathophysiological framework of neonatal hyperparathyroidism, provides counseling recommendations, and summarizes treatment options.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Urology & Nephrology
William G. Goodman, Donald T. Ward, Kevin J. Martin, Debra Drayer, Carol Moore, Jiahong Xu, James Lai, Yun Chon, Edward. F. Nemeth
Summary: The study suggests that hyperphosphatemia may attenuate the therapeutic response to calcimimetic agents, but the efficacy of treatment with calcimimetic agents remains strong in managing secondary hyperparathyroidism among dialysis patients, even with elevated serum phosphorus levels.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2022)
Review
Endocrinology & Metabolism
Manju Chandran, John P. Bilezikian, Joel Lau, Reshma Rajeev, Samantha Peiling Yang, Miny Samuel, Rajeev Parameswaran
Summary: This study conducted a systematic review and meta-analysis to evaluate the safety and efficacy of Cinacalcet in patients with primary hyperparathyroidism (PHPT). The findings suggest that Cinacalcet can effectively lower serum calcium and PTH levels in PHPT patients, with a greater impact on calcium levels in the short term. The drug is safe with tolerable side effects.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
(2022)
Article
Medicine, General & Internal
Nagihan Bestepe, Fatma Neslihan Cuhaci, Burcak Polat, Berna Evranos Ogmen, Didem Ozdemir, Reyhan Ersoy, Bekir Cakir
Summary: This study aimed to investigate the diagnostic value of serum calcium/phosphorus ratio in primary hyperparathyroidism screening. The results showed that the calcium/phosphorus ratio is a simple and inexpensive method for primary hyperparathyroidism screening when a cutoff value of 2.59 is used.
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
(2022)
Review
Endocrinology & Metabolism
Kelly L. Roszko, Lyndsay M. Stapleton Smith, Ananth Sridhar, Mary Scott Roberts, Iris R. Hartley, Rachel Gafni, Michael T. Collins, Jonathan C. Fox, Edward F. Nemeth
Summary: Autosomal dominant hypocalcemia type 1 (ADH1) is a rare form of hypoparathyroidism caused by activating variants of the calcium-sensing receptor gene (CASR). Patients often present with severe symptoms at diagnosis and have an increased risk of renal complications after receiving conventional therapy.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Tomohiro Saito, Masahide Mizobuchi, Mariko Sakai, Takehisa Kawata, Tetsuya Kitayama, Tadashi Kato, Taihei Suzuki, Hiroaki Ogata, Fumihiko Koiwa, Hirokazu Honda
Summary: This study investigated the effect of calcimimetic evocalcet (Evo) on the expression of parathyroid calcium-sensing receptor (CaSR) and vitamin D receptor (VDR). The results showed that Evo and cinacalcet (Cina) can increase the expression of CaSR and VDR in uremic rats with secondary hyperparathyroidism (SHPT). The upregulation of these receptors may provide better control of mineral and bone disorder markers.
Article
Biochemistry & Molecular Biology
Tomohiro Saito, Masahide Mizobuchi, Mariko Sakai, Takehisa Kawata, Tetsuya Kitayama, Tadashi Kato, Taihei Suzuki, Hiroaki Ogata, Fumihiko Koiwa, Hirokazu Honda
Summary: It has been found that the expression of calcium and vitamin D receptors is reduced during hemodialysis. However, treatment with calcimimetic evocalcet (Evo) can enhance the expression of these receptors in hemodialysis patients, which contributes to better control of mineral and bone disorder markers.
Article
Surgery
Xin Li, Yao Lu, Ling Zhang, Aiping Song, Honglei Zhang, Bo Pang, Jun Liu, Xiaoliang Sun, Haoyang Ji, Linping Huang, Meng Yang
Summary: The expression of calcium-sensing receptor (CaSR) was found to be downregulated in both primary and secondary hyperparathyroidism (HPT). However, secondary HPT exhibited higher levels of CaSR mRNA and protein compared to primary HPT.
Article
Endocrinology & Metabolism
Jakob Hoeppner, Sabrina Lais, Claudia Roll, Andreas Wegener-Panzer, Dagmar Wieczorek, Wolfgang Hoegler, Corinna Grasemann
Summary: Familial hypocalciuric hypercalcemia (FHH) is a benign endocrine condition caused by heterozygous inactivating mutations in the calcium sensing receptor (CaSR). This condition can lead to neonatal hyperparathyroidism if the mutation is paternally inherited, but can be successfully treated with cinacalcet. Patients with FHH should be aware of the risk of neonatal disease manifestation and monitor pregnancies and neonates accordingly.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Endocrinology & Metabolism
Judit Toke, Gabor Czirjak, Peter Enyedi, Miklos Toth
Summary: The calcium-sensing receptor (CaSR) serves as the major mechanism for detecting extracellular calcium concentration, playing a crucial role in calcium homeostasis and being associated with diseases characterized by serum calcium level changes. Mutations in the CaSR gene can either lead to increased sensitivity to calcium causing hypocalcemia, or resistance to extracellular calcium. Common polymorphisms of the CaSR gene have been reported to have no direct effect on calcium homeostasis, but may be linked to an increased risk of malignancies.
